1082040-43-4

Basic information

• Product Name: 6-Fluoro-1H-indole-4-carboxylic acid methyl ester
• Synonyms: 6-Fluoro-1H-indole-4-carboxylic acid methyl ester;1H-Indole-4-carboxylic acid, 6-fluoro-, Methyl ester;Methyl 6-fluoro-1H-indole-4-carboxylate;6-Fluoro indole-4-Methylcarboxylate;methyl 6-Fluoroindole-4-carboxylate;Rucaparib Intermediate 2
• CAS NO: 1082040-43-4
• Molecular Formula: C₁₀H₈FNO₂
• Molecular Weight: 193
• Mol File: 1082040-43-4.mol

Chemical Properties

• Boiling Point: 343.7±27.0 °C(Predicted)
• Appearance: /
• Density: 1.341±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 15.20±0.30(Predicted)
• CAS DataBase Reference: 6-Fluoro-1H-indole-4-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Fluoro-1H-indole-4-carboxylic acid methyl ester(1082040-43-4)
• EPA Substance Registry System: 6-Fluoro-1H-indole-4-carboxylic acid methyl ester(1082040-43-4)

Safety Data

• Hazardous Substances Data: 1082040-43-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Fluoro-1H-indole-4-carboxylic acid methyl ester is used as a building block for the synthesis of PARP (Poly ADP-ribose polymerase) inhibitors. These inhibitors play a crucial role in the treatment of various types of cancer by targeting the DNA repair mechanism in cancer cells, leading to their death while sparing normal cells.
Used in Anticancer Drug Development:
6-Fluoro-1H-indole-4-carboxylic acid methyl ester is used as a key intermediate in the development of anti-ovarian cancer drugs, such as rucaparib. This drug has shown promising results in the treatment of ovarian cancer by inhibiting the PARP enzyme, which is overexpressed in these cancer cells, thus disrupting their DNA repair mechanism and inducing cell death.

Upstream product

• 175278-29-2 5-fluoro-2-methylbenzoic acid methyl ester 
• 697739-03-0 5-fluoro-2-methyl-3-nitrobenzoic acid methyl ester 
• 850462-64-5 5-fluoro-2-methyl-3-nitrobenzoic acid 
• 33184-16-6 5-fluoro-2-methylbenzoic acid 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 3891-07-4 N-(2-Hydroxyethyl)phthalimide 
• 1408282-25-6 3-(2-(phthalimido)ethyl)-6-fluoro-1H-indole-4-carboxylic acid methyl ester 
• 283173-50-2 Rucaparib 
• 1408282-26-7 6-fluoro-3,10-diazatricyclo[6.4.1.0^4,13]trideca-1,4⁽¹³⁾,5,7-tetraen-9-one 

Relevant articles and documents

Multkilogram scale-up of a reductive alkylation route to a novel PARP inhibitor

Novel PARP inhibitor 1 is a promising new candidate for treatment of breast and ovarian cancer. A modified synthetic route to 1 has been developed and demonstrated on 7 kg scale. In order to scale up the synthesis to multikilogram scale, several synthetic challenges needed to be overcome. The key issues included significant thermal hazards present in a Leimgruber-Batcho indole synthesis, a low-yielding side-chain installation, a nonrobust Suzuki coupling and hydrogen cyanide generation during a reductive amination. In addition to these issues, changing from intravenous to oral delivery required a new salt form and therefore a new crystallization procedure. This contribution describes development work to solve these issues and scaling up of the new process in the pilot plant.

ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS

The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

Preparation method of ovarian cancer resistance medicine Rucaparib key intermediate

The invention discloses a preparation method of an ovarian cancer resistance medicine Rucaparib key intermediate, and relates to preparation of medical intermediates. A compound 1 takes methyl alcoholand cyclohexane as solvents, toluenesulfonic acid serve